BiotechTube
Fina Biotech

Fina Biotech

Barcelona, Spain· Est.
finabiotech.es
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

Founded in 2015, Fina Biotech is a private, pre-revenue diagnostics company developing non-invasive tests for bladder cancer. Its core asset is the UROBEST® assay, which appears to be in a commercial or late-stage development phase, positioning the company to address a significant unmet need in urological oncology. Operating from Barcelona, the company is likely in a capital-intensive R&D and commercialization phase, with its success heavily dependent on clinical validation, market adoption of UROBEST®, and the progression of its pipeline projects.

OncologyUrology

Technology Platform

Non-invasive diagnostic assay platform likely based on biomarker detection in urine (e.g., molecular or immunoassay techniques).

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

Significant unmet need for accurate, non-invasive alternatives to cystoscopy in bladder cancer surveillance, representing a large and recurring market.
Successful validation of the UROBEST® platform could enable expansion into other cancer types or disease areas using similar liquid biopsy technology.

Risk Factors

High competition in the non-invasive bladder cancer diagnostic space from established and emerging tests.
Achieving clinical adoption and favorable reimbursement from European healthcare systems presents a major commercial and regulatory hurdle.

Competitive Landscape

The market for non-invasive bladder cancer diagnostics includes established urine-based tests like NMP22, BTA stat, and UroVysion (FISH), as well as newer molecular and genomic assays from companies like Pacific Edge (Cxbladder), Arquer Diagnostics, and others. Fina Biotech must differentiate UROBEST® on performance, cost, and ease of use.

More companies in Diagnostics & Precision Medicine →More companies in Spain →